Even if earnings beat, we might not see a massive upside swing. Subsequent guidance upgrades as well as analyst upgrades will be the catalyst needed to push higher. I see AFFY flirting with the 2007 highs (high 30's, low 40's) within six months.
Affymax is now shifting from research mode to growth mode.
Omontys is expected to reach 15 Mil$ in this qrt. This push much over 60 Mil$/year, because of PROGRESSIVE growing sales, I'd say 100 Mil$ at least in next 12 months... only a guess of mine (conservative).
Fifty-fifty with Takeda (I guess is more than 50% for AFFY).... 50 Mil$.
Net profit in sales.... 45 Mil$ (90% is typical in bio).
15x multiplier... market cap of near 700 Mil$....... then add up some assets and company value...
We're actually priced in projection of annual 60/100 Mil$ in gross sales.
All we have to look at is the progression in sales growth.
And the fact 91/92% is held by big investors and the YMB is desert, is another good point..... :)